References
- G. Manning, D. B. Whyte, R. Martinez,T. Hunter, and S. Sudarsanam, Theprotein kinase complement of the humangenome, Science, 298, 1912 (2002) https://doi.org/10.1126/science.1075762
- M. A. Pearson and D. Fabbro, Targetingprotein kinases in cancer therapy: asuccess?, Expert Rev. Anticancer Ther.,4, 1113 (2004) https://doi.org/10.1586/14737140.4.6.1113
- S. Klein and A. Levitzki, Signaltransduction therapy for cancer - whithernow?, Curro Signal Transduction Ther., 1,1 (2006) https://doi.org/10.2174/157436206775269244
- S. S. Sridhar, D. Hedley, and L. L. Siu,Raf kinase as a target for anticancertherapeutics, Mol. Cancer Ther., 4, 677(2005) https://doi.org/10.1158/1535-7163.MCT-04-0297
- J. Klysik, S. j. Theroux, j. M. Sedivy, j.S. Moffit, and K. Boekelheide, Signalingcrossroads: The function of Raf kinaseinhibitory protein in cancer, the centralnervous system and reproduction. Cell.Signalling, 20, 1 (2008) https://doi.org/10.1016/j.cellsig.2007.07.003
- X. Xu, R. M. Quiros, P. Gattuso, K. B.Ain, and R. A. Prinz, High prevalence ofb-RAF gene mutation in papillary thyroidcarcinomas and thyroid tumor cell lines.Cancer Res., 63, 4561 (2003)
- I. Niculescu-Duvaz, E. Roman, ES. R.Whittaker, R. Kirk, I. j. Scanlon, L. C.Davies, D. Niculescu-Duvaz, R Marais,and C. J. Springer, Novel inhibitors ofB-RAF based on a disubstituted pyrazinescaffold. generation of a nanomolar lead.J Med. Chem, 49, 407 (2006) https://doi.org/10.1021/jm050983g
- J. Zimmermann, E. Buchdunger, H. Mett,T. Meyer, N. B. Lydon, and P. Traxler,Phenylarnino-pyrirnidine (P AP)derivatives:a new class of potent andhighly selective PDGF -receptorautophosphorylation inhibitors, Bioorg.Med Chem Lett, 6, 1221 (1996) https://doi.org/10.1016/0960-894X(96)00197-7
- A. A. San Juan, StructUral. investigationof PAP derivatives by CoMFA andCoMSIA reveals novel insight towardsinhibition of Bcr-Abl oncoprotein, J Mol.Graphics Modell. 26, 482 (2007) https://doi.org/10.1016/j.jmgm.2007.03.001
- I. Collins and P. Workman, Design anddevelopment of signal transductioninhibitors for cancer treatment: experienceand challenges with kinase targets. CurroSignal Transduction Ther., 1, 13 (2006)
- E. Weisberg, P. Manely, j. Mestan, S.Cowan-Jacob, A. Ray, and j. D. Griffin,AMN107 (nilotinib): a novel and selectiveinhibitor of BCR-ABL. Br. J Cancer, 94,1765 (2006) https://doi.org/10.1038/sj.bjc.6603170
- H. Adams, S. R. Batten, G. M. Davies,M. B. Duriska, j. C. Jeffery, P. Jensen, j.Lu, G. R. Motson, S. j. Coles, M. B.Hursthouse, and M. D. Ward, New bis-,tris- and tetrakis(pyrazolyI)borate ligandswith 3-pyridyl and 4-pyridyl substituents:synthesis and coordination chemistry.Dalton Trans., 11, 1910 (1910)
- W.-S. Huang and W. C. An efficientsynthesis of nilotinib (AMN107).Shakespeare, Synthesis, 14, 2121 (2007)
- I. M. EI-Deeb, j. C. Ryu, and S. H. Lee,Synthesis of New N-arylpyrirnidin-2-amine derivatives using a palladiumcatalyst, Molecules, 13, 818 (2008) https://doi.org/10.3390/molecules13040818
- S. M. Wilhelm, C.; Carter, L. Tang, D.Wilkie, A. McNabola, H. Rong, C. Chen,X. Zhang, P. Vincent, M. McHugh, Y.Cao, j. Shujath, S. Gawlak, D. Eveleigh,B. Rowley, L. Liu, L. Adnane, M. Lynch,D. Auclair, I. Taylor, R. Gedrich, A.Voznesensky, B. Riedl, L. E. Post, G.Bollag, and P. A. Trail, BAY 43-9006exhibits broad spectrum oral antitumoractivity and targets the RAF !MEK!ERKpathway and receptor tyrosine kinasesinvolved in tumor progression andangiogenesis, Cancer Res., 64, 7099 (2004) https://doi.org/10.1158/0008-5472.CAN-04-1443